KR20020059727A - 고차 핵산 기재 구조 - Google Patents

고차 핵산 기재 구조 Download PDF

Info

Publication number
KR20020059727A
KR20020059727A KR1020027006140A KR20027006140A KR20020059727A KR 20020059727 A KR20020059727 A KR 20020059727A KR 1020027006140 A KR1020027006140 A KR 1020027006140A KR 20027006140 A KR20027006140 A KR 20027006140A KR 20020059727 A KR20020059727 A KR 20020059727A
Authority
KR
South Korea
Prior art keywords
nucleic acid
molecules
polynucleic acid
acid structure
molecule
Prior art date
Application number
KR1020027006140A
Other languages
English (en)
Korean (ko)
Inventor
카르프랑크제이
카터그라햄
Original Assignee
플레믹 크리스티안
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9926810.4A external-priority patent/GB9926810D0/en
Priority claimed from GB0011126A external-priority patent/GB0011126D0/en
Application filed by 플레믹 크리스티안, 메르크 파텐트 게엠베하 filed Critical 플레믹 크리스티안
Publication of KR20020059727A publication Critical patent/KR20020059727A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020027006140A 1999-11-13 2000-11-13 고차 핵산 기재 구조 KR20020059727A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9926810.4 1999-11-13
GBGB9926810.4A GB9926810D0 (en) 1999-11-13 1999-11-13 High order nucleic acid-based structures
GB0011126.0 2000-05-10
GB0011126A GB0011126D0 (en) 2000-05-10 2000-05-10 High order nucleic acid-based structures
PCT/EP2000/011197 WO2001036624A1 (en) 1999-11-13 2000-11-13 High order nucleic acid based structures

Publications (1)

Publication Number Publication Date
KR20020059727A true KR20020059727A (ko) 2002-07-13

Family

ID=26244234

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027006140A KR20020059727A (ko) 1999-11-13 2000-11-13 고차 핵산 기재 구조

Country Status (16)

Country Link
EP (1) EP1228201A1 (zh)
JP (1) JP2003522524A (zh)
KR (1) KR20020059727A (zh)
CN (1) CN1390253A (zh)
AU (1) AU782880B2 (zh)
BR (1) BR0015484A (zh)
CA (1) CA2391084A1 (zh)
CZ (1) CZ20021472A3 (zh)
HK (1) HK1052529A1 (zh)
HU (1) HUP0203914A2 (zh)
MX (1) MXPA02004727A (zh)
NO (1) NO20022231L (zh)
PL (1) PL358811A1 (zh)
RU (1) RU2002113755A (zh)
SK (1) SK6042002A3 (zh)
WO (1) WO2001036624A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210031494A (ko) * 2018-07-12 2021-03-19 바이 야오 쥐 다 (베이징) 나노바이오 테크놀로지 컴퍼니 리미티드 핵산 나노입자, 이를 포함하는 약물 조성물, 독소루비신 함유 약물 및 그 제조 방법

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US9796749B2 (en) 2011-08-05 2017-10-24 President And Fellows Of Harvard College Compositions and methods relating to nucleic acid nano- and micro-technology
US10604543B2 (en) 2012-07-24 2020-03-31 President And Fellows Of Harvard College Self-assembly of nucleic acid nanostructures
WO2014074597A1 (en) 2012-11-06 2014-05-15 President And Fellows Of Harvard College Compositions and methods relating to complex nucleic acid nanostructures
WO2015070080A2 (en) * 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Nucleic acid nanostructures for in vivo agent delivery
CN106488883A (zh) 2014-05-22 2017-03-08 哈佛学院院长及董事 可扩展的基于核酸的纳米制造
WO2017156264A1 (en) 2016-03-11 2017-09-14 Children's Medical Center Corporation Nucleic acid nanoswitch catenanes
EP4071159B1 (en) 2016-08-02 2023-12-13 President and Fellows of Harvard College Crisscross cooperative self-assembly
CN110711254B (zh) * 2018-07-12 2022-07-26 百药智达（北京）纳米生物技术有限公司 核酸纳米颗粒及包含其的药物组合物
CN110960542B (zh) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 含吡柔比星的药物、其制备方法、药物组合物及其应用
CN110960534B (zh) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 含五氟尿嘧啶的药物、其制备方法、药物组合物及其应用
CN110960530B (zh) * 2018-09-30 2022-07-22 百药智达（北京）纳米生物技术有限公司 含他克林的药物、其制备方法、药物组合物及其应用
CN110960536B (zh) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 含阿司匹林的药物、其制备方法、药物组合物及应用
CN110960690B (zh) * 2018-09-30 2022-07-22 百药智达（北京）纳米生物技术有限公司 含表柔比星的药物、其制备方法、药物组合物及其应用
CN111053765B (zh) * 2018-10-16 2022-07-26 百药智达（北京）纳米生物技术有限公司 含紫杉醇的药物、其制备方法、药物组合物及应用
CN111068065B (zh) * 2018-10-22 2022-07-26 百药智达（北京）纳米生物技术有限公司 含奥沙利铂的药物、其制备方法、药物组合物及其应用
CN111084887B (zh) * 2018-10-23 2022-07-22 百药智达（北京）纳米生物技术有限公司 含黄酮的药物、其制备方法、药物组合物及应用
CN111096965B (zh) * 2018-10-29 2022-07-26 百药智达（北京）纳米生物技术有限公司 含双氢青蒿素的药物、其制备方法、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000813A1 (en) * 1983-08-03 1985-02-28 The Research Foundation Of State University Of New Nucleic acid branched junctions with precisely defined migrational mobility
US5386020A (en) * 1991-01-10 1995-01-31 New York University Multiply connected, three-dimensional nucleic acid structures
US5278051A (en) * 1991-12-12 1994-01-11 New York University Construction of geometrical objects from polynucleotides
US6072044A (en) * 1996-04-26 2000-06-06 New York University Nanoconstructions of geometrical objects and lattices from antiparallel nucleic acid double crossover molecules

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210031494A (ko) * 2018-07-12 2021-03-19 바이 야오 쥐 다 (베이징) 나노바이오 테크놀로지 컴퍼니 리미티드 핵산 나노입자, 이를 포함하는 약물 조성물, 독소루비신 함유 약물 및 그 제조 방법

Also Published As

Publication number Publication date
PL358811A1 (en) 2004-08-23
AU782880B2 (en) 2005-09-08
AU2000101A (en) 2001-05-30
CZ20021472A3 (cs) 2002-07-17
WO2001036624A1 (en) 2001-05-25
MXPA02004727A (es) 2002-08-30
CA2391084A1 (en) 2001-05-25
JP2003522524A (ja) 2003-07-29
SK6042002A3 (en) 2002-12-03
EP1228201A1 (en) 2002-08-07
HUP0203914A2 (en) 2003-03-28
CN1390253A (zh) 2003-01-08
HK1052529A1 (zh) 2003-09-19
RU2002113755A (ru) 2004-01-10
NO20022231D0 (no) 2002-05-10
NO20022231L (no) 2002-05-10
BR0015484A (pt) 2002-07-02

Similar Documents

Publication Publication Date Title
KR20020059727A (ko) 고차 핵산 기재 구조
US7179894B2 (en) Combinatorial selection of oligonucleotide aptamers
AU680405B2 (en) Nucleozymes
US6140490A (en) High affinity nucleic acid ligands of complement system proteins
AU777043B2 (en) Nucleic acid ligands to CD40ligand
US6605713B1 (en) Mirror-symmetrical selection and evolution of nucleic acids
Lin et al. Peptide conjugation to an in vitro-selected DNA ligand improves enzyme inhibition.
Kopylov et al. Combinatorial chemistry of nucleic acids: SELEX
JPH09511641A (ja) 自己集合性多量体核酸構築物
Nakamura et al. RNA plasticity and selectivity applicable to therapeutics and novel biosensor development
CN102171339A (zh) 针对ngf的适体及其用途
JPH11505527A (ja) 鏡像異性体リガンドの同定
EP1404867A2 (en) Oligonucleotide transfection screening method
WO1996011010A1 (en) Bridged and unbridged quadruplex/duplex oligonucleotides
JP2002523059A (ja) 基質置換での酵素活性スクリーン
EP0888374B1 (en) HIGH AFFINITY NUCLEIC ACID LIGANDS OF THE COMPLEMENT SYSTEM PROTEIN C1q
ZA200204728B (en) High order nucleic acid based structures.
AU2014238740B2 (en) Aptamer to IL-17 and use thereof
WO2020204151A1 (ja) Ｆｇｆ９に対するアプタマー及びその使用
WO2010107405A1 (ru) Способ получения пептидов, специфично распознающих определённые типы клеток и предназначенных для терапевтических целей
CN118460655A (zh) 抑制FXI基因表达的siRNA的制备方法
JP2024046855A (ja) インテグリンα７β１受容体に対する結合能を有するＤＮＡアプタマー
Polisky Progress towards Therapeutic Application of SELEX-derived Aptamers
CN118460649A (zh) 一种Vutrisiran的制备方法
WO1996010176A1 (en) Means for reversibly inactivating biological molecules

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid